Fractalkine/CX3CL1 in rheumatoid arthritis.

摘要: Fractalkine is a CX3C chemokine that exists in both membrane-bound and soluble forms. Interaction between fractalkine its unique receptor (CX3CR1) induces cell adhesion, chemotaxis, crawling, "accessory cell" activity, survival. The serum level of elevated patients with rheumatoid arthritis (RA) correlated disease activity. Peripheral blood CD16+  monocytes subset T cells express CX3CR1, while expressed on fibroblast-like synoviocytes endothelial the synovial tissue RA. expression enhanced by tumor necrosis factor-α interferon-γ, it promotes migration monocytes, cells, osteoclast precursors into RA tissue. also production inflammatory mediators macrophages, synoviocytes. Moreover, angiogenesis osteoclastogenesis. In an animal model RA, was improved abrogation fractalkine. Recently, clinical trial anti-fractalkine monoclonal antibody for treatment commenced Japan. We review multiple roles pathogenesis potential as therapeutic target this disease.